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Abstract 
Background: HIV-1 Tat protein is implicated in HIV-neuropathogenesis. Tat C31S polymorphism (TatCS) has been 
associated with milder neuropathology in vitro and in animal models but this has not been addressed in a cohort of 
HIV-infected adults or children.
Methods: HIV viral load (VL) in plasma and cerebrospinal fluid (CSF) were determined and plasma HIV tat gene was 
sequenced. Neurodevelopmental assessment was performed using Bayley Scales of Infant Development III (BSID-III), 
with scores standardized to Malawian norms. The association between TatCS and BSID-III scores was evaluated using 
multivariate linear regression.
Results: Neurodevelopmental assessment and HIV tat genotyping were available for 33 children. Mean age was 19.4 
(SD 7.1) months, mean log VL was 5.9 copies/mL (SD 0.1) in plasma and 3.9 copies/mL (SD 0.9) in CSF. The prevalence 
of TatCC was 27 %. Z-scores for BSID-III subtests ranged from −1.3 to −3.9. TatCC was not associated with higher BSID-III 
z-scores.
Conclusions: The hypothesis of milder neuropathology in individuals infected with HIV TatCS was not confirmed 
in this small cohort of Malawian children. Future studies of tat genotype and neurocognitive disorder should be 
performed using larger sample sizes and investigate if this finding is due to differences in HIV neuropathogenesis 
between children and adults.
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Background
Although prevention of mother-to-child transmission 
(PMTCT) of HIV has significantly decreased the inci-
dence of pediatric HIV, approximately 240,000 children 
were newly infected with HIV in 2013 [1]. HIV infection 
negatively impacts the neurological development of 
children, with symptoms ranging from mild neurode-
velopmental delays to severe neurocognitive and motor 
impairments [2–4]. While early initiation of anti-ret-
roviral therapy (ART) can prevent or delay the onset of 
HIV-associated neurological disorders (HAND) [5, 6], 
only one in every seven children living with HIV in sub-
Saharan Africa receive ART [7].
Virologic factors that contribute to neurodevelopment 
are poorly understood, particularly in children. HIV-1 Tat 
protein has been implicated in both directly [8] and indi-
rectly [9] inducing monocyte chemotaxis, damaging the 
blood brain barrier, direct neurotoxicity and augmenting 
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monocyte infiltration across the blood–brain barrier. Tat 
is released from infected cells and causes direct damage 
to the central nervous system (CNS) white matter [10, 
11] and promotes indirect damage through the induc-
tion of chemokines and cytokines [12]. A key molecular 
determinant of neuropathogenesis in HIV-1 Tat is the 
C30C31 dicysteine motif (TatCC) and in a given individ-
ual’s plasma, nearly all viruses display the same genotype. 
For example, Tat in HIV-1 subtype B isolates contains a 
highly conserved (99  %) C30C31 motif, which mediates 
its ability to induce β chemokines and promote monocyte 
chemotaxis [13]—features that play a key role in HAND. 
In contrast, approximately 90 % of subtype C HIV-1 iso-
lates worldwide have a C31S (TatCS) polymorphism [13], 
which has been linked with defective monocyte chemo-
taxis. We have previously shown that an Indian subtype 
C HIV-1 isolate with TatCS, when compared to US sub-
type B isolate, displayed decreased in  vitro chemokine 
induction, decreased monocyte recruitment by infected 
macrophages, and in a mouse model for HIV encephali-
tis [14], caused milder neurodegeneration and decreased 
cognitive impairment following intracranial injection 
of HIV-infected monocyte-derived macrophages [15]. 
Furthermore, subtype C HIV TatCS causes decreased 
N-methyl d-aspartate (NMDA) receptor induced neuro-
toxicity [16] and neuronal cell death [17] compared with 
subtype B HIV Tat.
The importance of Tat dicysteine motif in HAND is 
further underscored by the geographic variability of HIV-
associated dementia (HAD) in adults in regions where 
subtype C predominates. In India, where subtype C infec-
tion is predominant, HAD prevalence of 2–6 % has been 
reported [18, 19]. In contrast, South Africa and Botswana, 
also countries with predominantly subtype C infections, 
have reported a 25–30 % prevalence of HAD [20, 21]. The 
higher incidence of HAD correlates with a higher preva-
lence of intact Tat dicysteine motif in Southern African 
isolates (11–22  % of subtype C HIV isolates from Bot-
swana and South Africa), while the lower incidence of 
HAD in India correlates with a lower prevalence of HIV-1 
isolates with Tat C30C31 motif [22]. Thus, the variation 
in the prevalence of HAND between different regions 
with subtype C HIV epidemics appears to correlate with 
regional differences in the frequency of the subtype C 
HIV-1 isolates bearing Tat with an intact dicysteine motif 
[22]. This hypothesis has been further validated through 
in vitro experiments and mouse models of HIV encepha-
litis using a Zambian HIV-1 subtype C isolate with an 
intact dicysteine motif [22]. However, the tat genotype 
and HAD prevalence in the same cohort has not been 
confirmed so far. A recent study in adults in South Africa 
showed no significant cognitive differences between 
adults with subtype C HIV-1 with TatC31S as compared 
to those with the dicysteine motif [23]. However, to date, 
viral genotypic differences related to pediatric HIV neu-
rodevelopmental delay have not been evaluated.
We evaluated the relationship between the HIV-1 Tat 
dicysteine motif and neurodevelopmental delay in HIV-
infected children in Malawi using the Bayley Scales of 
Infant Development III (BSID-III). We hypothesized that 
HIV-1 Tat dicysteine motif is associated with neurode-
velopmental delay in children infected with HIV-1 sub-
type C.
Methods
Study population
Children were eligible to participate if HIV-infected, age 
2–36 months, ART-naïve, but eligible for ART and if their 
primary caregiver had no chronic illnesses other than 
HIV that might impede the daily activities or neurode-
velopment of the child. Children were recruited through 
either the pediatric HIV clinic or the emergency depart-
ment at Queen Elizabeth Central Hospital in Blantyre, 
Malawi between June 2009 and June 2010. Children with 
a history of severe birth asphyxia, cerebral malaria, men-
ingitis, a congenital malformation or chronic medical that 
may interfere with neurodevelopment were excluded.
Children recruited through the HIV clinic had to dem-
onstrate delay for one or more neurodevelopmental mile-
stones on a parental screening questionnaire, whereas 
those recruited through the emergency department had 
to have a clinical indication for a lumbar puncture.
Laboratory and neurodevelopmental evaluations
Participating children underwent neurodevelopmental 
testing with the BSID-III, to assess motor (fine and gross), 
cognitive, and language (expressive and receptive commu-
nication) development [24]. Neurodevelopmental assess-
ment was performed at enrolment for children recruited 
through the HIV clinic and at 1-month follow-up visit 
among children recruited through the emergency depart-
ment, to ensure that the acute illness did not interfere 
with the neurodevelopmental assessment. The BSID-III 
was administered in the local language of Chichewa by a 
study pediatrician or nurse trained in administration of 
the BSID-III. Scores were interpreted using normative 
data from Malawi [25]. Neurological development for each 
child was classified as normal (between mean and ±1 SD), 
mild delay (between −1 and −2 SD), severely delayed (>−2 
SD), above normal (between +1 and +2 SD) or advanced 
(>+2 SD above mean) for each of the five subtests.
Blood and cerebrospinal fluid (CSF) were collected 
and viral loads (VL) were determined using Abbott 
RealTime HIV-1 assay with a lower limit of quantitation 
of <320 copies/mL. Plasma HIV RNA was used to create 
cDNA through reverse transcription, and viral exon I tat 
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sequences (nucleotides 1–214, corresponding to codons 
1–70), which includes the codons for amino acids 30 and 
31 were determined. The amino acid at Tat codon 31, 
predicted using the nucleotide sequence, was used in the 
statistical analysis.
Statistical analysis
Using Stata 12.0 (College Station, TX), we created sepa-
rate linear regression models to assess the association 
between the outcomes of fine motor, gross motor, cog-
nitive, expressive communication and receptive com-
munication z-scores with TatCC as the primary exposure 
variable of interest. Potential covariates included mater-
nal ART use (dichotomous), exposure to PMTCT 
(dichotomous), breastfeeding  >6  months of life (dichot-
omous), breastfeeding at enrollment (dichotomous), 
gender, log plasma VL (continuous), log CSF VL (con-
tinuous), CSF-to-plasma VL ratio (continuous), and 
maternal age (continuous). Frequency distributions were 
calculated for these covariates among subjects with TatCS 
and TatCC. Covariates were examined for their relation-
ship with neurodevelopmental z-scores using t-test with 
unequal variances, Mann–Whitney U-test, Pearson’s cor-
relation, and Spearman’s correlation, as appropriate.
Separate multivariable models were created for each 
neurodevelopmental z-score using an a priori approach in 
which variables were chosen based on biological plausibil-
ity of confounding the relationship between exposure and 
outcome. In addition, covariates with missing values could 
not be included in the model as this lead to small effective 
sample sizes. Based on these criteria, the variables chosen 
to include were age, log plasma VL, and log CSF VL. To 
assess for normality of the linear regression model, the 
standardized residuals were plotted on a histogram and 
p–p plot. Outliers with a Cook’s distance greater than 4/n 
were excluded. Additional models using robust regression 
diagnostics were created by excluding outliers with Cook’s 
distance >1. The assumptions of equal variances and line-
arity were tested using a residuals-versus-fitted plot. Mul-
ticollinearity was tested by using variance inflation factors 
(VIF) with a cut-off of >10.
We also performed a sensitivity analysis to determine 
if the exclusion of the six subjects lacking Tat sequenc-
ing information affected the estimate of the association 
between exposure and outcome.
Ethics statement
Institutional Review Board approval was received from 
the College of Medicine in Blantyre, Malawi, the Uni-
versity of North Carolina in Chapel Hill, NC, and Albert 
Einstein College of Medicine in Bronx, NY. Written 
informed consent was obtained from all parents or 
guardians.
Results
Characteristics of study population
Of the 46 HIV-infected children enrolled, 39 completed 
neurodevelopmental assessments, and 33 had isolates 
available for genetic sequencing to determine the pre-
dicted amino acid sequence at Tat codon 31 (Fig.  1). 
Of the 33 children included in the analysis, 32 were 
recruited through the HIV clinic, and one through the 
emergency department. No HIV-negative children were 
enrolled. The mean age was 19.4 (SD 7.1) months, mean 
log plasma VL was 5.9 (SD 0.1) copies/mL, and mean 
log CSF VL was 3.9 (SD 0.9) copies/mL, and 44.8  % of 
all mothers in the study received single-dose nevirapine 
(sdNVP) for PMTCT. Compared to children with TatCS, 
children with TatCC were more likely to have received 
sdNVP for PMTCT (p = 0.041), have higher log plasma 
VL (p  =  0.008) and tended to have higher log CSF VL 
(p = 0.139) (Table 1). There was no difference in socioec-
onomic conditions such as ownership of goods, housing 
materials and access to running water between the two 
groups (data not shown).
Exposure (HIV Tat motif) and outcome 
(neurodevelopment) in 33 Malawian children
The prevalence of the TatCC was 24 % among all (n = 41) 
pediatric isolates available and 27  % among those who 
also completed BSID-III evaluations (n  =  33) (see 
Table 1).
All children had moderate to severe delay in at least one 
domain: 88 % (n = 29) for cognitive development, 88 % 
(n = 29) for expressive communication, 60 % (n = 20) for 
receptive communication, 78 % (n =  26) for fine motor 
and 97  % (n  =  32) for gross motor development (not 
shown). Unadjusted neurodevelopmental z-scores for 
each domain were plotted on a box and whiskers plot and 
shown in Fig.  2. Compared to the Malawian norm, the 
HIV infected children enrolled in the study had delayed 
development with z-scores on BSID-III ranging from 
−3.9 (SD 1.6) for gross motor development to −1.3 (SD 
0.9) for receptive communication (Table 1; Fig. 2).
Association between HIV Tat motif and outcome 
(neurodevelopment)
The z-scores for the five subtests of the BSID-III did 
not differ between children infected with TatCC and 
TatCS HIV virus. In multivariate analyses, adjusting for 
age, log plasma VL, and log CSF VL in the final model, 
there was no significant association between TatCC and 
neurodevelopment, including fine motor (p  =  0.314), 
gross motor (p =  0.732), cognitive (p =  0.553), expres-
sive communication (p = 0.579) and receptive commu-
nication z-scores (p = 0.805) (Table 2). The results were 
similar when using robust regression analysis. Figure  3 
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Fig. 1 Study enrollment flow chart. Subjects were recruited either with neurodevelopmental delays through the cotrimoxazole (COT) HIV clinic 
or with acute neurological deficit requiring a lumbar puncture through the emergency department. Seven subjects died or were lost to follow-up. 
Thirty subjects completed full or partial Bayley III assessments and 33 of those subjects had isolates available for genetic sequencing
Table 1 Demographic data
* Sample size: age, gender, log viral load, log CSF viral load, viral load ratio, (n = 33); maternal age (n = 30); maternal ART use, PMTCT, breastfed for >6months (n = 29); 
breastfeeding at enrollment (n = 31)
a ART—antiretroviral therapy
b PMTCT—prevention of mother to child transmission; the use of antepartum antiretroviral therapy to prevent the peripartum transmission of HIV; all mothers that 
received PMTCT, received single-dose nevirapine (sdNVP)
Tat C31S polymorphism  
(TatCS) n = 24 (72.7 %)
Dicysteine motif  
(TatCC) n = 9 (27.3 %)
p-value
Age (months) mean ± SD* 20.2 ± 8.0 17.1 ± 7.1 0.261 t-test
Gender (% male) 45.8 44.4 >0.999 Fisher’s exact
Maternal age (years) mean ± SD 27.6 ± 4.8 26.7 ± 4.7 0.622 t-test, unequal
Log plasma viral load (copies/mL) mean ± SD 5.7 ± 0.6 6.4 ± 0.5 0.008 t-test, unequal
Log CSF viral load (copies/mL) mean ± SD 3.8 ± 1.0 4.3 ± 0.5 0.139 t-test
Viral load ratio (CSF:plasma) mean ± SD 0.04 ± 0.10 0.01 ± 0.01 0.401 t-test
Maternal ARTa use (% on ART) 19.1 0.0 0.552 Fisher’s exact
PMTCTb (% that received sdNVP) 30.0 77.8 0.041 Fisher’s exact
Breastfeeding at enrollment (%) 30.4 25.0 >0.999 Fisher’s exact
Breastfed for >6months (%) 60.9 83.3 0.633 Fisher’s exact
Neurodevelopmental scores (z-scores) t-test, unequal
 Fine motor −1.9 ± 1.1 −2.4 ± 1.4 0.361
 Gross motor −4.0 ± 1.7 −3.9 ± 1.3 0.783
 Cognitive −1.9 ± 1.1 −1.5 ± 0.8 0.199
 Expressive communication −1.9 ± 1.2 −1.9 ± 0.9 0.869
 Receptive communication −1.4 ± 0.9 −1.3 ± 0.7 0.916
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illustrates the adjusted point estimates and 95  % confi-
dence intervals for the association between TatCC and 
the five domains of neurological development measured 
by the BSID-III.
Children excluded because of lack of Tat sequenc-
ing information were on average 5 months younger, and 
had higher gross motor and expressive communication 
z-scores compared to children with Tat information. In 
a sensitivity analysis to assess a potential bias introduced 
by the exclusion of these children, we found that assign-
ing children with missing Tat information either as all 
TatCC or as all TatCS did not change our final result of a 
lack of association observed between Tat sequence and 
neurodevelopmental delay.
Discussion
In this cross-sectional study of HIV-infected children in 
Malawi, we found, contradictory to our hypothesis, the 
presence of TatCC variants was not significantly associ-
ated with neurodevelopmental severity in multivariate 
analysis. This may be related to (1) differences in HIV-
associated neuropathogenesis between children and 
adults, (2) small sample size or other factors.
It is possible that TatCC variants are associated with the 
occurrence of HIV neuropathogenesis but not the sever-
ity thereof, an issue we could not conclusively assess as 
all participating children presented with neurodevel-
opmental delay. Underlying differences in neuropathol-
ogy may explain the results identified in this study. HIV 
Fig. 2 Neurodevelopmental z-scores obtained by the Bayley III Scales of Infant and Toddler Development standardized to pediatric Malawian 
norms. Box and whiskers plot mean and range for unadjusted neurodevelopmental z-scores, including gross motor, cognitive, expressive communi-
cation, and receptive communication
Table 2 P-values for Tat-CC in univariate and multivariable analysis
Adjusted for age, log plasma VL, and log CSF VL
Fine motor Gross motor Cognitive Expressive  
communication
Receptive  
communication
Univariate analysis t-test, unequal variances 0.361 0.783 0.199 0.869 0.916
Multivariable analysis 0.846 0.974 0.155 0.848 0.376
Multivariable analysis excluding Cooks > 4/n 0.314 0.732 0.553 0.579 0.805
Multivariable analysis with robust regression 0.715 0.949 0.222 0.909 0.323
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neuropathy is a result of chronic HIV infection that 
results in the infiltration of activated monocytes into 
the brain, which leads to the production of Tat, gp120, 
cytokines, and other neurotoxic viral proteins [26]. In 
children with HIV-associated neuropathy, both the dura-
tion of HIV infection and the associated inflammation 
are shorter when compared with adults with HAND. 
Additionally, infants and children have rapidly develop-
ing brains, which undergo increases in white matter size, 
maturation of myelination, and increase in the number 
of neuronal axons [27]. Central nervous system (CNS) 
pathology of children with AIDS frequently involves 
global anoxic-ischemic and necrotizing encephalomy-
elopathies [28, 29] which differs from the pathology seen 
in adults consisting of fronto-temporal atrophy, diffuse 
parenchymal nodules, as well as perivascular mononu-
clear infiltrates [30]. Radiographic evaluations support 
white matter damage, which differs between neona-
tal and adult brains in response to ischemic injury [27]. 
Immunologic differences also distinguish pediatric and 
adult HIV-associated neuropathy. CNS vascular inflam-
mation found in pediatric AIDS consists of transmural 
and perivascular mononuclear infiltrates consisting pri-
marily of CD3+  and CD8+  T-lymphocytes, in contrast 
to the inflammatory lesions found in adult patients with 
HIV-1 encephalopathy in which monocytes and mac-
rophages are the predominant mononuclear cells [31], 
suggesting the immunologic and inflammatory basis of 
disease in children is fundamentally different from that 
found in adults. A CNS compartmentalization study con-
ducted on the same study population showed that only 
10–20 % of the children had HIV variants compartmen-
talized in the CSF [32] that have evolved to use low levels 
of CD4, a characteristic of macrophage-tropic isolates. 
This supports the hypothesis that CNS HIV replication in 
the majority of the children occurs primarily in T-cells. 
Although prior in  vitro research has shown that sub-
type C HIV-1 Tat with an intact dicysteine motif induces 
greater CCL-2 induction, monocyte recruitment, and 
neuropathology, the effects of HIV-1 Tat with an intact 
dicysteine motif on T-lymphocytes are unknown and 
merits evaluation. As previously noted, prior clinical data 
shows that Southern African countries with predomi-
nantly subtype C infection show both a higher prevalence 
of HAD and a higher proportion of subtype C HIV-1 
with a TatCC motif [1, 21, 22, 33, 34]; however, all of these 
results were obtained from studies in adults. This is the 
first study to evaluate the neurodevelopmental outcomes 
in children infected with subtype C HIV-1 with the TatCC 
motif.
In the neurocognitive evaluation conducted by Paul 
et al. South African adult individuals infected with clade 
C HIV-1 with TatCC were compared to those infected 
with clade C HIV-1 with TatCS motif [23]. They found no 
differences in the neurocognitive defects between the two 
groups. This adult study, like the current pediatric study, 
also relied on plasma-derived HIV-1 sequences to deter-
mine the Tat genotype. It is known that HIV-1 can be 
compartmentalized in the brain [32] which could mean 
that it may be more directly relevant to correlate the cog-
nitive defects to brain- or CSF-derived HIV-1 sequences 
than to plasma. Furthermore, studies focused on Tat 
also do not take into account the role of gp120, another 
source of neuronal dysfunction. Our recent report has 
shown that while the gp120 of Indian subtype C HIV-1 
is non-neurovirulent, that of Southern African subtype C 
HIV-1 displayed robust neurovirulence [35].
Our findings should be interpreted in light of the study 
limitations. First, the sample size was small and informa-
tion on some covariates was incomplete, which restricted 
our ability to adjust for confounding variables. Most impor-
tantly, even though in bivariate analysis we observed that 
children with TatCC were more likely to have higher plasma 
VL and were more likely to have received sdNVP for 
PMTCT (p = 0.041) compared to children with TatCS, we 
were only able to include plasma VL and not PMTCT in the 
multivariate model. This may have biased the association to 
the null and thus contributed to the lack of a statistically 
significant relationship between HIV-1 TatCC motif and 
developmental delay. Second, data on the plasma CD4 or 
CD8 lymphocyte count was not available. Low plasma CD4 
counts have been associated with neurocognitive dysfunc-
tion in children [36] and low plasma CD8 counts are asso-
ciated with the risk of neurological impairment in children 
[37]. Third, the cross-sectional study design hindered the 
ability to infer causation and allowed for the introduction of 
biases. Survival bias may have occurred and influenced the 
interpretation of our findings. Although there may be some 
Fig. 3 Adjusted coefficients for TatCC. For each of the five subtests, 
the adjusted point estimate and 95 % lower confidence limit (LCL) 
and upper confidence limit (UCL) for the association for TatCC is plot-
ted on the linear scale
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bias due to exclusion of children without Tat information, 
sensitivity analysis suggest that this did not influence our 
conclusions. In our analysis, children with HIV TatCC vari-
ants had a significantly higher mean plasma VL than HIV 
TatCS variants (p =  0.008; t-test, unequal variances). It is 
possible that HIV-infected children with TatCC variants did 
not survive as long as children with TatCS variants. If such 
survival bias occurred, it could appear that children with 
TatCS variants have more severe neurodevelopmental delay. 
Finally, we were unable to assess the association between 
TatCC and the severity of neurodevelopmental delay as all 
children included in the analysis presented with neurode-
velopmental delay in at least one domain. A control group 
of HIV-infected children without neurodevelopmental 
delay could have contributed valuable information but was 
precluded given ethical and cultural concerns of perform-
ing a lumbar puncture in this population.
Conclusions
In this study of 33 Malawian ART-naïve HIV-1 subtype 
C infected children with neurodevelopmental delay, we 
observed that the presence of HIV TatCC motif was not 
associated with the severity of developmental delay in 
children with HIV type C infection. This may be due to 
differences in HIV-1 neuropathogenesis in children as 
compared to adults but demonstrating this hypothesis 
will require studies with larger sample size.
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